| Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k. | |
| | |
MedLine Citation:
|
PMID: 19679688 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Rash has been reported in up to 76% of patients with lung cancer who have received the epidermal growth factor receptor inhibitor (EGFRI) erlotinib. It has also been observed in patients treated with other agents that have a similar mode of action. Erlotinib-associated skin toxicity typically presents as a papulopustular, follicular, acneiform rash. In most cases, it is mild, transient, and well tolerated, but in 8%-12% of patients, it may be sufficiently severe and persistent to necessitate intervention. Increasingly strong data suggest that the incidence and severity of skin toxicity may be predictive of response and survival in patients treated with erlotinib. This has prompted some clinicians to consider "treatment to rash" (i.e., increasing the dosage until a rash appears) as a rational management strategy. In 2007, an international consensus was developed for the management of EGFRI-associated skin toxicity. Subsequently, a multidisciplinary group (the U.K. Erlotinib Skin Toxicity Management Consensus Group) met to validate and modify the international recommendations for U.K. use, with specific reference to erlotinib. Although many aspects of the international consensus were approved by the group as being relevant for the U.K., certain parts were modified. The resulting expert opinion is a practical and workable version of the international proposal that considers all applicable national issues regarding the management of erlotinib-associated skin toxicity. |
| | |
Authors:
|
Nicholas Thatcher; Marianne Nicolson; Richard W Groves; Jeremy Steele; Beth Eaby; Joyce Dunlop; John McPhelim; Rajinder Nijjar; Ijeoma Ukachukwu; |
Related Documents
:
|
1983938 - Subspecialists and internal medicine: a perspective. 12733798 - Can corals be harvested sustainably? 10261298 - Plateauing and productivity. 1453248 - Internal medicine training in ambulatory gynecology. 22273408 - A performance improvement process to tackle tachysystole. 9107058 - Treatment options for distal ureteral stones. |
Publication Detail:
|
Type: Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't Date: 2009-08-13 |
Journal Detail:
|
Title: The oncologist Volume: 14 ISSN: 1549-490X ISO Abbreviation: Oncologist Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-08-31 Completed Date: 2009-12-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9607837 Medline TA: Oncologist Country: United States |
Other Details:
|
Languages: eng Pagination: 840-7 Citation Subset: IM |
Affiliation:
|
Department of Medical Oncology, Manchester, M20 4BX, UK. nick.thatcher@christie-tr.nwest.nhs.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Drug Eruptions
/
etiology,
therapy* Great Britain Humans Protein Kinase Inhibitors / adverse effects*, therapeutic use Quinazolines / adverse effects*, therapeutic use Survival Rate |
| Chemical | |
Reg. No./Substance:
|
0/Protein Kinase Inhibitors; 0/Quinazolines; 0/erlotinib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Minimum inhibitory and minimum fungicidal concentrations of amphotericin B, itraconazole, posaconazo...
Next Document: The future burden of cancer in London compared with England.